Novo Nordisk (NVO), Omega Therapeutics (OMGA) and Cellarity announced that Novo Nordisk has entered into separate research collaborations with each company. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. The Cellarity collaboration aims to unravel novel biological drivers of MASH and will leverage Cellarity’s platform to develop a small molecule therapy against this disease. These are the first two programs signed under the framework collaboration between Flagship Pioneering and Novo Nordisk to leverage Flagship’s bioplatform companies to develop novel treatment approaches for cardiometabolic diseases.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Poised to Perform in 2024
- Gen Z Stocks: The Path from Gambling to Investment
- Alkermes to sell manufacturing facility in Ireland to Novo Nordisk for $92.5M
- WW falls after Oprah reveals use of weight-loss drug to People
- ABBV, NVO, or LLY: Which Healthcare Stock Could Generate the Highest Returns?
